Immunome Reports Positive Phase 3 Data for Varegacestat, Plans NDA Submission
Event summary
- Immunome's Phase 3 RINGSIDE trial for varegacestat met primary endpoint, showing 84% reduction in disease progression risk (HR=0.16, p<0.0001).
- Company plans to submit NDA for varegacestat in Q2 2026 following positive desmoid tumor trial results.
- Cash position of $653.5M as of December 31, 2025, expected to fund operations into 2028.
- Phase 1 study for IM-1021 ongoing with objective responses in B-cell lymphoma patients observed.
The big picture
Immunome's positive Phase 3 data for varegacestat positions it as a potential first-in-class therapy for desmoid tumors, a rare cancer indication with limited treatment options. The company's focus on ADCs and proprietary payload HC74 aligns with the industry trend toward targeted oncology therapies that overcome drug resistance. With a strong cash position, Immunome is well-funded to pursue multiple regulatory and development milestones in 2026.
What we're watching
- Regulatory Approval
- Whether the NDA submission for varegacestat will be accepted and approved by the FDA in 2026.
- Pipeline Progress
- The pace at which Immunome advances its ADC pipeline, with IND submissions planned for three programs in 2026.
- Financial Runway
- How Immunome manages its cash position to sustain operations through 2028 amid ongoing R&D expenses.
Our editorial coverage:
Related topics